ArticleScientific reports2025
An end-to-end mass spectrometry data classification model with a unified architecture.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Mass spectrometry, known for its high sensitivity, selectivity, rich structural information, and rapid analysis capabilities, is widely used in disease diagnosis and bioanalysis. Despite progress in classification methods/tools for data collection in the past decade, problems such as complex data processing, weak model characterization, and large interbatch differences persist. To address these problems, we present MS-DREDFeaMiC, a deep neural network framework for disease diagnosis and bioanalysis via mass spectrometry data that enables end-to-end training. The trained MS-DREDFeaMiC can integrate mixed features, reduce interbatch differences, and enhance feature distinctions among categories. To demonstrate its wide applicability, ten comparative experiments were conducted with seven public datasets and one self-constructed dataset, and MS-DREDFeaMiC yielded state-of-the-art results. MS-DREDFeaMiC achieved average accuracies that were 6.6% and 6.3% higher than those of Transformer and Mamba, respectively. We anticipate that MS-DREDFeaMiC can be directly applied to routine disease diagnosis and that any mass spectrometry-based classification studies can benefit from such an end-to-end trained model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.